Metastatic Melanoma
358
44
84
143
Key Insights
Highlights
Success Rate
64% trial completion
Published Results
109 trials with published results (30%)
Research Maturity
143 completed trials (40% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
22.1%
79 terminated out of 358 trials
64.4%
-22.1% vs benchmark
5%
18 trials in Phase 3/4
76%
109 of 143 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 143 completed trials
Clinical Trials (358)
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release